Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73301
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73301
Character Range: 6986–7716

73301              A test of tumour tissue from a patient with advanced (FIGO III‑IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]‑ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS)                                                                                                                                                                                                                                1,200.00

                   Applicable once per primary tumour diagnosis